Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
According to the study, a single dose of the company's proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas' position in the gene editing market is strengthened by the result, enhancing the company's potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting.
A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients' genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an 'in vivo gene editing upregulation strategy.'
While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Read More: and
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating
CG Oncology, Inc. (NASDAQ:CGON) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 17, Morgan Stanley raised the firm's price target on CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52, while maintaining an Overweight rating on the shares. A researcher in a laboratory examining a vial of oncolytic herpes simplex virus, demonstrating the company's commitment to finding a cure for cancer. The firm told investors in a research note that although the non-muscle invasive bladder cancer space has undergone recent and anticipated approvals, the space is comprehensive enough to accommodate multiple players. It thus considers cretostimogene to be meaningfully differentiated by its safety data and durability, along with having 'best-in-disease potential' that supports an optimistic rating for the company. CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market?
This company has reported accelerating revenue growth in recent quarters, and in the latest period, revenue soared more than 150%. After great gains last year, the stock slipped 45% in the first half of this year. 10 stocks we like better than SoundHound AI › Last year was a big one for artificial intelligence (AI) stocks, with companies in the sector leading all three major benchmarks to gains. Though the momentum halted temporarily earlier this year, as investors worried about the impact of import tariffs on the economy, this positive energy has returned. Investors are optimistic that trade talks will result in lower-than-expected tariffs, limiting the negative effects on companies, and that has buoyed interest in growth players, including AI stocks. Some AI stocks, though, have yet to feel the rebound. Considering the long-term AI growth story hasn't changed, these players may offer you bargain buying opportunities today. Let's consider one in particular. This AI stock surged more than 800% in 2024 but dropped 45% in the first half of this year. Meanwhile, it's a specialist in its field, one with a total addressable market of more than $140 billion. Is this player a buy right now? The AI stock I'm talking about is SoundHound AI (NASDAQ: SOUN), a company with expertise in voice AI, reinforced by more than 190 granted patents. Though other companies, even big players such as Amazon or Microsoft, are involved in the field, SoundHound stands out thanks to its speech-to-meaning technology. The company translates speech directly to meaning, bypassing the common step of translating speech to text first, therefore gaining in speed and quality. Customers clearly like SoundHound's offerings, as revenue has taken off, and the company has signed deals across industries. This is a key point because, in its earlier days, SoundHound primarily served the automobile industry. This strength in fields such as healthcare, retail, travel, and more, as well as the fact that no customer represents more than 10% of revenue, greatly reduces SoundHound's risk. That's because if one customer or industry cuts spending, others may compensate. SoundHound's revenue in the recent quarter advanced 151% to about $29 million, which is great. But what's even better is that the company still has plenty of room for growth, considering its current revenue level and the total addressable market of $140 billion, which spans 14 different industries. And the company has three ways to generate revenue: through royalties on its products, subscriptions for services, and taking additional revenue from the use of its products and services. Of course, despite SoundHound's expertise in the field, the company still faces the risk of major rivals, such as those mentioned above, gaining market share due to their immense resources. That's what makes SoundHound a stock that carries some risk right now, and even though the stock has slipped this year, the decline looks small compared to the gain posted last year. These factors could limit SoundHound's growth in the near term. Still, the company has seen growth accelerate in recent quarters, from 89% in the third quarter of last year to 101% in the fourth quarter and even higher in the most recent period. Further, as mentioned above, SoundHound may still be in its early stages of growth. So, what does this mean for you as an investor? Should you buy SoundHound now on the dip? The answer depends on your investment strategy. If you're a cautious investor, you're probably better off buying a larger, well-established player, such as Amazon or Microsoft, that may benefit from voice AI but also from broader, profitable businesses. Over time, they've proven their earnings and stock performance strengths. If you're an aggressive investor, though, SoundHound looks like a fantastic AI buy right now. The stock has slipped from its high, offering you a lower entry point. Revenue has clearly accelerated in recent quarters, and the company has successfully broadened its customer base across industries. On top of that, I like that SoundHound is financially healthy, with no debt and $246 million in cash. All this makes it a great AI stock to get in on right now and hang on to as its growth story develops. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
